248 related articles for article (PubMed ID: 28771657)
21. Ixekizumab treatment for psoriasis: integrated efficacy analysis of three double-blinded, controlled studies (UNCOVER-1, UNCOVER-2, UNCOVER-3).
Papp KA; Leonardi CL; Blauvelt A; Reich K; Korman NJ; Ohtsuki M; Paul C; Ball S; Cameron GS; Erickson J; Zhang L; Mallbris L; Griffiths CEM
Br J Dermatol; 2018 Mar; 178(3):674-681. PubMed ID: 28991370
[TBL] [Abstract][Full Text] [Related]
22. Absolute and relative psoriasis area and severity index (PASI) treatment goals and their association with health-related quality of life.
Gerdes S; Körber A; Biermann M; Karnthaler C; Reinhardt M
J Dermatolog Treat; 2020 Aug; 31(5):470-475. PubMed ID: 32202943
[No Abstract] [Full Text] [Related]
23. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
Chaptini C; Quinn S; Marshman G
Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
[TBL] [Abstract][Full Text] [Related]
24. A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.
Lebwohl MG; Kircik L; Callis Duffin K; Pariser D; Hooper M; Wenkert D; Thompson EH; Yang J; Kricorian G; Koo J
J Am Acad Dermatol; 2013 Sep; 69(3):385-92. PubMed ID: 23643256
[TBL] [Abstract][Full Text] [Related]
25. Comparison of the 1- and 5-year effectiveness of adalimumab, etanercept and ustekinumab in patients with psoriasis in daily clinical practice: results from the prospective BioCAPTURE registry.
Zweegers J; Groenewoud JMM; van den Reek JMPA; Otero ME; van de Kerkhof PCM; Driessen RJB; van Lümig PPM; Njoo MD; Ossenkoppele PM; Mommers JM; Koetsier MIA; Arnold WP; Andriessen MPM; Kuijpers ALA; Berends MAM; Kievit W; de Jong EMGJ
Br J Dermatol; 2017 Apr; 176(4):1001-1009. PubMed ID: 27579864
[TBL] [Abstract][Full Text] [Related]
26. Real-world outcomes in 2646 psoriasis patients: one in five has PASI ≥10 and/or DLQI ≥10 under ongoing systemic therapy.
Norlin JM; Calara PS; Persson U; Schmitt-Egenolf M
J Dermatolog Treat; 2017 Sep; 28(6):500-504. PubMed ID: 28132580
[TBL] [Abstract][Full Text] [Related]
27. Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.
Kalb RE; Blauvelt A; Sofen HL; Chevrier M; Amato D; Calabro S; Wang J; Schenkel B; Gottlieb AB
J Drugs Dermatol; 2013 Aug; 12(8):874-80. PubMed ID: 23986160
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety observed during 24 weeks of efalizumab therapy in patients with moderate to severe plaque psoriasis.
Menter A; Gordon K; Carey W; Hamilton T; Glazer S; Caro I; Li N; Gulliver W
Arch Dermatol; 2005 Jan; 141(1):31-8. PubMed ID: 15655139
[TBL] [Abstract][Full Text] [Related]
29. Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3).
Blauvelt A; Papp KA; Griffiths CEM; Puig L; Weisman J; Dutronc Y; Kerr LF; Ilo D; Mallbris L; Augustin M
Am J Clin Dermatol; 2017 Apr; 18(2):273-280. PubMed ID: 28074446
[TBL] [Abstract][Full Text] [Related]
30. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
31. The effect of bodyweight on the efficacy and safety of ixekizumab: results from an integrated database of three randomised, controlled Phase 3 studies of patients with moderate-to-severe plaque psoriasis.
Reich K; Puig L; Mallbris L; Zhang L; Osuntokun O; Leonardi C
J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1196-1207. PubMed ID: 28370467
[TBL] [Abstract][Full Text] [Related]
32. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
Mattei PL; Corey KC; Kimball AB
J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
[TBL] [Abstract][Full Text] [Related]
33. Pattern of response in patients with moderate-to-severe psoriasis treated with etanercept.
Griffiths CE; Sterry W; Brock F; Dilleen M; Stefanidis D; Germain JM; Mallbris L
Br J Dermatol; 2015 Jan; 172(1):230-8. PubMed ID: 24861696
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Adalimumab and Etanercept for the Treatment of Moderate to Severe Psoriasis: An Indirect Comparison Using Individual Patient Data from Randomized Trials.
Papp KA; Yang M; Sundaram M; Jarvis J; Betts KA; Bao Y; Signorovitch JE
Value Health; 2018 Jan; 21(1):1-8. PubMed ID: 29304933
[TBL] [Abstract][Full Text] [Related]
35. Treating psoriasis with etanercept in italian clinical practice: prescribing practices and duration of remission following discontinuation.
Arcese A; Aste N; Bettacchi A; Camplone G; Cantoresi F; Caproni M; D'Amico D; Fabbri P; Filosa G; Galluccio A; Hansel K; Lisi P; Micali G; Musumeci ML; Nicolini M; Parodi A; Patania M; Pezza M; Potenza C; Richetta A; Simonacci M; Trevisan P; Valenti G; Calvieri S
Clin Drug Investig; 2010; 30(8):507-16. PubMed ID: 20586516
[TBL] [Abstract][Full Text] [Related]
36. Certolizumab pegol for the treatment of chronic plaque psoriasis: Results through 48 weeks of a phase 3, multicenter, randomized, double-blind, etanercept- and placebo-controlled study (CIMPACT).
Lebwohl M; Blauvelt A; Paul C; Sofen H; Węgłowska J; Piguet V; Burge D; Rolleri R; Drew J; Peterson L; Augustin M
J Am Acad Dermatol; 2018 Aug; 79(2):266-276.e5. PubMed ID: 29660425
[TBL] [Abstract][Full Text] [Related]
37. Long-Term Efficacy of Etanercept for Plaque-Type Psoriasis and Estimated Cost in Daily Clinical Practice.
María Fernández-Torres R; Paradela S; Fonseca E
Value Health; 2015 Dec; 18(8):1158-61. PubMed ID: 26686803
[TBL] [Abstract][Full Text] [Related]
38. Tildrakizumab efficacy and impact on quality of life up to 52 weeks in patients with moderate-to-severe psoriasis: a pooled analysis of two randomized controlled trials.
Blauvelt A; Sofen H; Papp K; Gooderham M; Tyring S; Zhao Y; Lowry S; Mendelsohn A; Parno J; Reich K
J Eur Acad Dermatol Venereol; 2019 Dec; 33(12):2305-2312. PubMed ID: 31407394
[TBL] [Abstract][Full Text] [Related]
39. The Dermatology Life Quality Index: assessing the efficacy of biological therapies for psoriasis.
Katugampola RP; Lewis VJ; Finlay AY
Br J Dermatol; 2007 May; 156(5):945-50. PubMed ID: 17388922
[TBL] [Abstract][Full Text] [Related]
40. The impact of PASI 75 and PASI 90 on quality of life in moderate to severe psoriasis patients.
Abrouk M; Nakamura M; Zhu TH; Farahnik B; Koo J; Bhutani T
J Dermatolog Treat; 2017 Sep; 28(6):488-491. PubMed ID: 28042711
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
